Billing Code 4410-09-M

DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION MANUFACTURER OF CONTROLLED SUBSTANCES NOTICE OF REGISTRATION JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC.

By Notice dated March 20, 2013, and published in the Federal Register on March 28, 2013, 78 FR 19017, Johnson Matthey Pharmaceutical Materials, Inc., Pharmaceutical Services, 25 Patton Road, Devens, Massachusetts 01434, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Amphetamine (1100)	II
Methylphenidate (1724)	II
Nabilone (7379)	II
Hydrocodone (9193)	II
Alfentanil (9737)	II
Remifentanil (9739)	II
Sufentanil (9740)	II

The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company's primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company's customers.

No comments or objections have been received. DEA has considered the factors in 21 USC § 823(a) and determined that the registration of Johnson Matthey Pharmaceutical Materials, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Johnson Matthey Pharmaceutical Materials, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 USC § 823(a), and in accordance with 21 CFR § 1301.33, the above named company

is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: July 23, 2013

[FR Doc. 2013-18333 Filed 07/30/2013 at 8:45 am;

Publication Date: 07/31/2013]